アンシムの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

アンシムの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7%で57億1,530万米ドルに成長します。予測期間の成長は、モノクローナル抗体生産の強化、新興市場におけるヘルスケアインフラの拡大、生物学的脅威の緩和戦略に対する世界の意識の高まりに起因すると考えられます。予測期間における主要動向としては、バイオ医薬品研究の高度化、バイオディフェンス構想における官民パートナーシップの拡大、医薬品生産の地域多様化の高まり、医薬品承認プロセスを加速するための規制経路の合理化の重視などが挙げられます。

細菌感染症の流行の高まりは、アンシム市場の成長を促進すると予想されます。有害な細菌が体内に侵入して増殖し、毒素を産生することで発生する細菌感染症は、抗生物質の過剰使用、世界の旅行、都市化、不衛生、ヘルスケア関連感染などの要因により増加傾向にあります。アンシムは、炭疽菌による細菌感染症である吸入炭疽の治療に用いられるモノクローナル抗体です。炭疽菌の毒素を中和し、細胞内への侵入を防ぐことで、その有害な作用を軽減します。例えば、世界保健機関（WHO）が2023年12月に発表した報告によると、ザンビアでは炭疽菌が疑われる症例が2022年9月から2023年1月までの42例から2023年11月までに684例と大幅に増加しており、うち4例が死亡しています。このような細菌感染、特に炭疽菌の有病率の上昇は、アンシム市場の成長を促進する重要な要因です。

アンシム市場の主要動向は、官民パートナーシップ（PPP）のような戦略的な国際契約を採用して技術統合を強化し、市場範囲を拡大することです。PPPは、政府機関と非公開製薬会社が共同で資金を拠出し、治療法を調査・研究・販売するもので、多くの場合、公衆衛生のニーズに対応するものです。例えば2022年4月、米国のバイオテクノロジー企業であるヒートバイオロジクスは、子会社のエルシス・セラピューティクスを通じてカナダ政府と565万米ドルの契約を締結しました。この契約は、カナダの国家緊急戦略備蓄にアンシムを供給するもので、炭疽菌による生物脅威に対抗することを目的とした薬剤の初の国際調達となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のアンシム：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアンシム市場：成長率分析
• 世界のアンシム市場の実績：規模と成長、2019～2024年
• 世界のアンシム市場の予測：規模と成長、2024～2029年、2034年
• 世界のアンシム：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のアンシム市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 成人用
• 小児用
• 世界のアンシム市場：臨床適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 吸入炭疽病の治療
• 吸入炭疽病の曝露後予防（PEP）
• 小児と成人における使用
• 世界のアンシム市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ドラッグストア
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のアンシム市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のアンシム市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• アンシム市場：競合情勢
• アンシム市場：企業プロファイル
  • Elusys Therapeutics Inc
  • Hikma Pharmaceuticals

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• アンシム市場、2029年：新たな機会を提供する国
• アンシム市場、2029年：新たな機会を提供するセグメント
• アンシム市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Anthim is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis infection. It works by binding to the anthrax toxin, preventing it from entering cells and causing damage.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of anthim include adult and pediatric formulations. Anthim (obiltoxaximab) is indicated for use in adults as part of the treatment regimen for inhalational anthrax caused by Bacillus anthracis. Its clinical indications include treating inhalational anthrax, providing post-exposure prophylaxis (PEP) for inhalational anthrax, and its use in both pediatric and adult populations. The various distribution channels include hospitals, drug stores, and other applications.

The anthim market research report is one of a series of new reports from The Business Research Company that provides anthim market statistics, including anthim industry global market size, regional shares, competitors with a anthim market share, detailed anthim market segments, market trends, and opportunities, and any further data you may need to thrive in the anthim industry. This anthim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthim market size is expected to see strong growth in the next few years. It will grow to $5,715.3 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to enhancing monoclonal antibody production, expanding healthcare infrastructure in emerging markets, and increasing global awareness of biological threat mitigation strategies. Major trends in the forecast period include advanced biopharmaceutical research, expanding public-private partnerships in biodefense initiatives, rising regional diversification in pharmaceutical production, and an emphasis on streamlined regulatory pathways to accelerate drug approval processes.

The rising prevalence of bacterial infections is expected to drive the growth of the anthim market. Bacterial infections, which occur when harmful bacteria invade the body, multiply, and produce toxins, are on the rise due to factors such as antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Anthim is a monoclonal antibody used to treat inhalation anthrax, a bacterial infection caused by Bacillus anthracis. It works by neutralizing the anthrax toxin and preventing it from entering cells, thus mitigating its harmful effects. For example, a report from the World Health Organization (WHO) in December 2023 revealed a significant increase in suspected anthrax cases in Zambia, from 42 cases between September 2022 and January 2023 to 684 cases by November 2023, including four deaths. This rising prevalence of bacterial infections, particularly anthrax, is a key factor fueling the growth of the anthim market.

A key trend in the anthim market is the adoption of strategic international contracts, such as public-private partnerships (PPPs), to enhance technology integration and expand market reach. PPPs involve collaborations between government agencies and private pharmaceutical companies to jointly fund, research, and distribute medical treatments, often addressing public health needs. For instance, in April 2022, Heat Biologics, a US-based biotechnology company, secured a $5.65 million contract with the Canadian government through its subsidiary Elusys Therapeutics. This contract involved supplying Anthim for the Canadian National Emergency Strategic Stockpile, marking the drug's first international procurement aimed at combating anthrax biothreats.

In April 2022, Heat Biologics, a US-based biotechnology company that offers pharmaceuticals, acquired Elusys Therapeutics expanding its biodefense portfolio. The acquisition allowed Heat Biologics to integrate Anthim into its RapidVax platform, enhance its manufacturing capabilities at a new facility in Kansas, and explore expanded global distribution opportunities. These developments highlight the growing strategic importance of Anthim in addressing anthrax threats and its potential for wider global distribution through partnerships and acquisitions.

Major players operating in the anthim market are Elusys Therapeutics Inc, and Hikma Pharmaceutical.

North America was the largest region in the anthim market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anthim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anthim market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthim market consists of sales of monoclonal antibodies, injectable solutions and emergency response treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthim Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anthim market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthim ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anthim market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Adult; Children
• 2) By Clinical Indications: Inhalational Anthrax Treatment; Post-Exposure Prophylaxis (PEP) For Inhalational Anthrax; Use In Pediatric And Adult Populations
• 3) By Application: Hospital; Drugs Store; Other Applications
• Companies Mentioned: Elusys Therapeutics Inc; Hikma Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anthim Market Characteristics

3. Anthim Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Anthim Market Trends And Strategies

5. Anthim Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Anthim Growth Analysis And Strategic Analysis Framework

• 6.1. Global Anthim PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Anthim Market Growth Rate Analysis
• 6.4. Global Anthim Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Anthim Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Anthim Total Addressable Market (TAM)

7. Global Anthim Market Pricing Analysis & Forecasts

8. Anthim Market Segmentation

• 8.1. Global Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Children
• 8.2. Global Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalational Anthrax Treatment
• Post-Exposure Prophylaxis (PEP) For Inhalational Anthrax
• Use In Pediatric And Adult Populations
• 8.3. Global Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Drugs Store
• Other Applications

9. Global Anthim Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Anthim Market Regional And Country Analysis

• 10.1. Global Anthim Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Anthim Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Anthim Market

• 11.1. Asia-Pacific Anthim Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Anthim Market

• 12.1. China Anthim Market Overview
• 12.2. China Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Anthim Market

• 13.1. India Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Anthim Market

• 14.1. Japan Anthim Market Overview
• 14.2. Japan Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Anthim Market

• 15.1. Australia Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Anthim Market

• 16.1. South Korea Anthim Market Overview
• 16.2. South Korea Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Anthim Market

• 17.1. Western Europe Anthim Market Overview
• 17.2. Western Europe Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Anthim Market

• 18.1. UK Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Anthim Market

• 19.1. Germany Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Anthim Market

• 20.1. France Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anthim Market

• 21.1. Eastern Europe Anthim Market Overview
• 21.2. Eastern Europe Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Anthim Market

• 22.1. North America Anthim Market Overview
• 22.2. North America Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Anthim Market

• 23.1. USA Anthim Market Overview
• 23.2. USA Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Anthim Market

• 24.1. Canada Anthim Market Overview
• 24.2. Canada Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Anthim Market

• 25.1. South America Anthim Market Overview
• 25.2. South America Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Anthim Market

• 26.1. Middle East Anthim Market Overview
• 26.2. Middle East Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Anthim Market

• 27.1. Africa Anthim Market Overview
• 27.2. Africa Anthim Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Anthim Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Anthim Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Anthim Market Competitive Landscape And Company Profiles

• 28.1. Anthim Market Competitive Landscape
• 28.2. Anthim Market Company Profiles
  • 28.2.1. Elusys Therapeutics Inc Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Hikma Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

29. Global Anthim Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Anthim Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Anthim Market

32. Recent Developments In The Anthim Market

33. Anthim Market High Potential Countries, Segments and Strategies

• 33.1 Anthim Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Anthim Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Anthim Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer